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We have previously reported that greater than 60% of human leukemic T-cell lines possess mutations in the p53 tumor suppressor gene. To determine whether T-cell acute lymphoblastic leukemia (T-ALL) patient samples possess p53 mutations, we screened peripheral blood-and bone marrow-derived leukemia samples, taken at diagnosis and at relapse, for p53 mutations. Exons 4 through 9 and selected intron regions of the p53 gene were analyzed using polymerase chain reaction-single-strand conformation polymorphism and direct sequencing. p53 mutations were found in 0 of 15 T-ALL diagnosis samples, as compared with 10 of 36 (28Y0) T-ALL relapse samples. To determine whether p53 mutations play a role in the recurrence (relapse) of T-ALL, t w o special groups of T-ALL patients were studied: (1) a group of 8 relapse patients whose disease was refractory t o chemotherapeutic treatment, and (2) a group of 6 "paired" T-ALL cell samples from patients for whom we possess both diagnosis and relapse samples. Three of 8 relapsed patients 53 BELONGS TO THE tumor suppressor class of genes whose function involves the negative regulation of cell growth. The loss of function of the p53 gene by deletion, mutation, or rearrangement may contribute to the genesis or progression of a wide variety of human cancers.',' Abnormalities in the p53 gene have been demonstrated in human carcinoma of the colorectum, 3 l i~e r ,~.~ bladder,8 and ovary'; in blast crisis chronic myelogenous and myelocytic leukemias'",''; in progressed adult T-cell le~kemia".'~; and in osteogenic sarcoma^.'^^'^ Several lines of evidence suggest that p53 mutatioddeletion is a late event in the development of cancer, because (1) in carcinomas of the colorectum, chromosome 17p deletions are associated with the transition from benign adenoma to malignant carcinoma'6; (2) the progression of brain tumors is associated with a clonal expansion of cells that have acquired a mutation in the p53 gene17; (3) the evolution of chronic-phase chronic myelogenous leukemia (CML) to myeloid blast crisis18-*" is associated with mutation of the p53 gene; and (4) the mutation of p53 and the loss of heterozygosity of chromosome 17p and 10 are associated with the progression of astrocytomas." However, mutations in p53 (37.5Y0) whose disease was refractory t o the reinduction of remission by chemotherapy possessed missense mutations of the p53 gene. All 3 cases had mutations in exon 5. Among the paired samples, 3 of 6 patients harbored p53 mutations at disease recurrence, but possessed only wild-type p53 alleles at diagnosis. One case had mutation on exon 4, l case in exon 5, and 1 case in exon 8 with loss of heterozygosity. These data clearly indicate that recurrence of T-ALL is associated with missense mutations in p53. Our results indicate that (1) mutations of p53 do occur in T-ALL in vivo, and such mutations are associated with the relapse phase of the disease; and (2) p53 mutation is involved in the progression of T-ALL. This conclusion is supported by our observation that the introduction of T-ALL-derived mutant p53 expression constructs into T-ALL cell lines further increases their growth rate in culture, enhances cell cloning in methylcellulose, and increases tumor formation in nude mice. 0 1994 by The American Society of Hematology.
have also. been found in the precancerous phases of adenocarcinomas and in adenomatous polyps of patients with familial polyposis coli,2z suggesting that p53 mutation may occur as an early event in carcinogenesis as well.
In our studies on the role of p53 in the pathogenesis of human T-cell acute lymphoblastic leukemia (T-ALL), we have shown that greater than 60% of T-ALL cell lines, all of which had been grown from relapse T-ALL cases, possess mutations on both p53
suggesting that p53 serves a critical role in the generation of the fully tumorigenic leukemic T cells. However, our experiments did not show whether these p53 mutations originated in vivo or whether the p53 gene had been mutated during cell line establishment in vitro, as has been shown to occur during the establishment of some rat embryo fibroblast cell lines.24 Gaidano et alZs and Jonveaux and BergerZ6 have reported that samples from T-ALL patients obtained at diagnosis harbor no mutations in the p53 gene. In all, these two groups studied 37 T-ALL diagnosis samples, all of which possessed only wild-type p53 alleles. Recently, we reported that T-ALL cell lines established in our laboratory from a patient sample taken at relapse possess the same p53 mutation found in the in vivo sample." Furthermore, no additional mutations of p53 OCcurred during establishment of the cell lines. These results suggest that the establishment of human T-ALL cell lines need not be associated with the induction of p53 mutations.
To study whether p53 mutations may be differentially associated with the relapse versus diagnosis phases of T-ALL, we used polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP)*' and direct sequencing of PCR-amplified fragments to study 15 cases of T-ALL at diagnosis and 36 cases at relapse. The results suggest that, in the patients studied, mutation of the p53 gene was associated with the clonal evolution that takes place during recurrence of the disease. 4, 5, 6 , and 8: 68°C for exon 7; 51°C for exon 9: for 2 minutes), and extension (72°C for 1 minute) were performed. Two microliters of the reaction mixture was diluted 25X in 0.1% sodium dodecyl sulfate (SDS)/IO mmol/L EDTA and further mixed I: I with a sequencing stop solution containing 20 mmoll L NaOH. Samples were heated to 95°C for 5 minutes and chilled on ice, and 3 pL was immediately loaded onto the gel. Gels were run at 4 W for 16 to 20 hours at room temperature. Autoradiography was performed with an intensifying screen for 6 to 24 hours. Because not all of the mutation bands were easily separated from normal germline bands with good resolution using one gel condition. three gel conditions were used for each sample: Direct sequencing of PCR products. Samples that were found by SSCP analysis to possess p53 mutations were sequenced to identify the nature of the mutation. Solid-phase sequencing of in vitro amplified genomic DNA was in which genomic DNA was amplified by PCR using biotinylated primers (Operon, Almeda, CA). One microgram of genomic DNA was used as template in a 100 pL PCR reaction with 12 pm01 of biotinylated primer and 36 pm01 of nonbiotinylated primer. Forty microliters of this reaction was incubated with magnetic beads conjugated covalently with streptavidin (Dynabeads M280-streptavidin: Dynal, Oslo, Norway) that were used to selectively immobilize the biotin-labeled PCR product and allow melting of the DNA duplex, followed by elution of the nonlabeled single strand. The immobilized single-strand DNA was then used as sequencing template using the Sequenase (US Biochemical CO, Cleveland, OH) protocol and an internal primer.
MATERIALS AND METHODS
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RESULTS
p53 mutation is a frequent genetic change in relapse T-ALL We used PCR-SSCP analysis to screen for p53 muta- Direct sequence analysis was performed on the 10 samples found to be positive for p53 mutations based on significant SSCP shifts. Most of the mutations found were missense mutations with single-base changes that encoded single amino acid substitutions in the p53 protein ( Table 1) . The majority of the mutations found are located in exon 5. One patient, PJN, had an intron 4 mutation. Although its biologic significance has not been studied further, its detection shows that cells harboring this mutation were selected for; hence, Homozygous" Heterozygous Homozygoust
93
Wild-type allele at this locus undetectable on sequencing gel, but no LOH by codon 72 polymorphism (see Fig 7) .
t Homozygous mutation verified by LOH determination (see Fig 7) . (Fig 3) . The apparent heterozygous nature of the mutations summarized in Table 1 may be caused by contamination of the leukemia samples with normal cells. Table 1 shows that at the time of DNA extraction the percent blast cells present in the patients' cell samples was at least 90%. The minority (wild-type) alleles detected could not have been caused by contamination with normal cells at the less than 10% level,
because in a mixture of mutant and wild-type DNA molecules the minority component is detectable on SSCP or sequencing gels only when present at the 20% level or higher.'" Hence, we conclude that the heterozygous nature of the mutations presented in Table 1 and in the corresponding figures represent mutations in one allele of the leukemia cells, whereas the other allele remains wild-type. To verify this conclusion, we have tested whether unrearranged (ie, germline) T-cell receptor (TCR) @-chain DNA could be demonstrated in the samples tested. Southern blots containing BumHI-digested genomic T-ALL DNA were hybridized with a probe specific for the human T@ locus. All 6 samples showed rearranged TCR@ bands, whereas in only one (ONN) patient sample could a band of apparent germline size be shown (data not shown). Hence, the p53 mutations shown in Table 1 
* CODON 175
For To determine the pathologic significance of p53 mutations in the recurrence (relapse) of T-ALL, a group of 6 "paired" T-ALL cell samples from patients for whom we possess both diagnosis and relapse samples were studied. PCR-SSCP and direct sequencing showed that none of the samples taken at diagnosis possessed p53 mutations, whereas 3 of 6 (50%) of the "paired" T-ALL samples studied harbored missense mutations at the relapse phase of the disease (Table 2 ). Figure 4 shows that CODON 135 a mutation was present in the leukemic cells of patient SMN at relapse. This mutation was absent from SMN's leukemic cells at diagnosis. PCR-direct sequencing data identify the nature of this mutation as a heterozygous missense mutation with a nucleotide change from CGT to CTT ( 1 IOArE + Leu). A heterozygous missense mutation with a nucleotide change from GCC to ACC (161"" -was found in the leukemic cells of patient SRN at relapse but not at diagnosis (Fig 5) . Furthermore, a homozygous missense mutation was detected in the leukemic cells of patient BTN at relapse but not at diagnosis. Figure 6 shows this mutation as found by SSCP (arrow). Direct sequencing data establish the nucleotide change at relapse, a codon change from CGG to GGG (282Arg -"ly).
We also studied whether p53 mutations were present in the cells of a group of 8 T-ALL relapse patients whose Homozygouslheterozygous mutations, genotype verified by codon 72 polymorphism (see Fig 7) .
For personal use only. on October 26, 2017. by guest www.bloodjournal.org disease was refractory to chemotherapeutic treatment.30.3' p53 exons 4 through 9 were screened for mutations using PCR-SSCP and direct sequencing. Three of 8 patients (37.5%) in this group possess p53 mutations as detected by PCR-SSCP. The p53 mutations in the group of refractory T-ALL cases all mapped to exon 5. Direct sequencing showed a homozygous missense mutation in codon 135 with a nucleotide change from TGC to TAC (135cys'Ty? in patient ASN (Table 3) . Leukemic cells of patients SRN and HAN harbored heterozygous missense mutations in codon 161 (GCC to ACC, 161 A'r ' and in codon 175 (CGC to GGC, 175Arg'C'y), respectively (Table 3) . Taken together, the presence of p53 mutations in 33% to 50% of relapse T-ALL cells in the different groups of patient samples studied suggests that p53 gene mutation is associated with the tumorigenic progression of relapse T-ALL cells.
Loss of heterozygosity at the p53 locus is an infrequent event in relapse T-ALL.. In human solid tumors, mutations of the p53 gene are frequently accompanied by the loss of heterozygosity of chromosome 17~13.1, the locus to which the p53 gene maps. We have previously reported that, in leukemia cell lines, both alleles of the p53 gene were often independently mutated without concomitant loss of heterozygosity at the 17~13.1 locus. To investigate whether loss of heterozygosity of p53 is a frequent event during recurrence of T-ALL, we used the known polymorphism at codon 72 of the human p53 This polymorphism is encoded by sequences in exon 4 of the p53 gene. The frequency of the 72"9-and the 72P"-encoding alleles (CGC and CCC, respectively) in the human population is 0.68 and 0.32, respectively.36 Thus, 4 4 % of the human population are heterozygous at this locus, whereas 46% and 10% encode homozy- 2 N N N N N N N N N N N gous (arg/arg)-or homozygous (pro/pro)-containing p53 proteins, respectively.
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We applied PCR-SSCP analysis of exon 4 to determine the polymorphic status at codon 72 in "paired" diagnosis and relapse leukemia samples taken from the same patients. Five of the 6 "paired" leukemia samples were heterozygous at codon 72 (4 of these are shown in Fig 7) , whereas 1 of the 6 "paired" patient samples, LMN, showed the homozygous arg/arg genotype at this position (Fig 7) . Only 1 of the 3 leukemia cases that harbored a p53 mutation at relapse (Table 2) , patient BTN, also underwent loss of heterozygosity upon leukemia relapse, by losing the arg-encoding p53 allele. As can be seen, the band of the amplified 72P"'-encoding alleles of patient BTN's relapse sample is of double intensity compared with the cases that were heterozygous at this codon. The status of codon 72 in the alleles carried by the leukemia cell lines MOLT-4 (arg/arg) and CEM (arg/ pro), which we have previously shown by immunoprecipitation to harbor alleles encoding homozygous (arg/arg) and heterozygous (arg/pro) p53 proteins, respectively," are shown as internal controls. Subsequent DNA sequencing has shown that the arginine allele was indeed lost during the recurrence (relapse) of disease in patient BTN (Fig 7, right) .
DISCUSSION
We have previously shown that acute lymphoblastic Tcell leukemia cell lines, all of which were derived from relapse T-ALL patients, frequently harbor mutations in the p53 gene.23 In contrast, T-ALL patient samples have been r e p~r t e d~' .~~ to lack such mutations. This suggested that p53 mutations that are found in cell lines may have been induced during in vitro establishment of the lines. However, in vitro mutation of p53 during the establishment of acute leukemia cell lines seemed unlikely because we have found in other experiments that, during establishment of multiple T-ALL cell lines, the p53 gene remained stably unaltered when compared with its state in the patients' leukemia cells. 27 This discrepancy was resolved in the current experiments by screening 15 untreated ("diagnosis") and 36 recurrent ("relapse") T-ALL cases, 12 of which were donated, pairwise, by the same patients at the diagnosis and at the relapse phases of their disease.
Among the 15 diagnosis T-ALL cases studied here, none possess p53 mutations in exons 4 through 9. Adding these 15 diagnosis cases to those reported by a total of 52 diagnosis T-ALL cases have now been reported to lack p53 mutations, supporting the notion that mutation of the p53 gene is not a causal event in the induction of childhood T-ALL. In contrast to diagnosis T-ALL cases, among 36 relapse cases studied, 10 (28%) harbored mutations in the p53 gene. Most (9 of 10) of these mutant p53 alleles specified missense mutations that gave rise to nonconservative amino acid exchanges, whereas 1 occurred in intron 4. The majority of these mutations were mapped to the highly conserved, T- The lack of p53 mutations in any of the "diagnosis" samples suggests, but does not prove beyond a reasonable doubt, that mutation of the p53 gene in relapse samples is specifically associated with the progression of the leukemic phenotype. To prove that p53 mutations in relapse leukemia represent clonal evolution events, we compared the status of the p53 gene in diagnosis and in relapse samples in a pairwise fashion. Six pairs of leukemia cell samples, each derived from the same patients at different points in the clinical course, were studied for the status of the p53 gene. All six diagnosis samples lacked detectable p53 mutations in exons 4 through 9, whereas in 3 of the 6 relapse samples (50%) a mutation had occurred in the p53 gene (Table 2) . Clearly, p53 mutation is associated with the clonal evolution of relapse leukemia in a significant fraction of cases. This result supports our previous finding that a significant fraction of acute leukemia cell lines, all derived from relapse cases, possess mutations in the p53 gene.
In some human solid tumors mutation of one p53 allele is often accompanied by the loss of the other p53 However, in acute leukemia cell lines loss of heterozygosity is an infrequent finding:3 and in the acute leukemia patient samples reported here, only 1 patient (BTN) among the 47 evaluable polymorphic cases displayed loss of heterozygosity of the p53 locus, as determined by the status of the polymorphic marker at codon 72. Although in greater than 50% of acute leukemia cell lines each p53 allele carried an independent mutation, in the current set of patient samples only 1 relapse case possessed two independent mutations (FMN, Table 1 ). These two mutations occurred on the same allele, as determined by molecular cloning (not shown). This discrepancy between leukemia cell lines and patient relapse samples suggests either that relapse leukemia cells possessing independent mutations in both alleles are favored during establishment in vitro, or that, in the lines, the second allele became mutated upon establishment.
Because the failure of chemotherapeutic treatment of acute childhood leukemia is often caused by the development of a drug-resistant clone, acute leukemias of patients who are refractory to the induction of remission might possess mutated p53 genes, as suggested by work of Cabanillas et 81'" and Chin et aL3' To test the possible correlation between refractoriness to remission induction and p53 mutation in acute T-cell leukemia, we tested a set of 8 refractory cases for the status of p53. Three of the 8 cases (37%) possess a mutation in the p53 gene (Table 3) . Interestingly, in these 3 refractory cases, the mutations were all located in exon 5, a hotspot of p53 mutations in human ~ancer.~" The possibility that these exon 5 mutations specifically affect the drug-resistant status of the leukemia cells raises interesting questions.
In each of the groups of relapse leukemia cases examined, the incidence of cases found to harbor p53 mutations probably represents a lower limit. Both the SSCP and the direct sequencing techniques fail to detect mutations that are present in less than 20% of the cell populations:' In addition, mutations may be present in exons other than exons 4 through 9 examined, or in introns. Alternatively, the frequency of mutations that we have found in relapse leukemias may represent only a fraction of the cases in which the wildtype suppressor function of p53 is inactivated. Relapse cases that lack detectable p53 mutations may have lost some of the p53 functions by inactivation of the p53 protein through complex formation with other cellular proteins, eg, mdmleukemias by means other than mutations are in progress.
It is important to consider why acute leukemia patient samples as well as cell lines infrequently display LOH at the p53 locus, whereas human solid tumors often show LOH at the p53 locus on chromosome 17p. The difference may The generation of malignant human solid tumors requires a series of 6 to 8 or more genetic alterations in the same ce11"; the malignant cells are "transformed" and transplantable, and possess many in vitro characteristics of "tumor cells." In contrast, in acute leukemias, malignancy is engendered by cells that have undergone fewer genetic alterations4 and that have few, if any, characteristics of "tumor cells."47 Specifically, acute leukemia cells are "malignant," ie, life-threatening, even though they merely display the characteristics of differentiation-inhibited, proliferating precursor cells (ibid), and may lack many or most of the in vitro criteria of "tumor cells," We propose that, in acute leukemia cells, mutation of each p53 allele provides the leukemic cell with a growth advantage through the e l i n a t i o n of normal suppressor functions and, especially, through the acquisition of dominant oncogenic functions (M. Hsiao, E. Dom, J. Yeargin, and M. Haas, manuscript submitted, and Dittmer et ala). Thus, whereas the acquisition of each dominantly acting mutated p53 allele is significant for the potentiation of the leukemic phenotype of acute leukemia cells, in solid tumors a fully tumorigenic and metastatic phenotype necessitates the loss of each functional p53 allele, hence the frequent loss of the functional allele through LOH.
